Tirzepatide is one of the most extensively studied peptides in recent years. Marketed under the brand names Mounjaro and Zepbound by Eli Lilly, it has drawn significant attention from the scientific community as the first dual GIP and GLP-1 receptor agonist validated in large-scale clinical trials. This guide covers its mechanism of action, available research data, and how it compares to semaglutide and retatrutide.
Note: This article is intended for scientific research purposes only. The peptides described are not intended for human or veterinary use.
About Scandinavian Pen Peptide: We are a specialist supplier of peptide research materials, committed to quality, scientific accuracy, and full transparency. All content is based exclusively on peer-reviewed publications and clinical trial data.
What is Tirzepatide?
Tirzepatide is a synthetic peptide consisting of 39 amino acids. Its structure is based on GIP (glucose-dependent insulinotropic polypeptide), with modifications that enable simultaneous binding to GLP-1 receptors. It is often referred to as a “twincretin” in the research literature — because it combines, in a single molecule, the actions of two separate incretin hormones.
A fatty acid chain extends its half-life to approximately five days, which explains the weekly dosing protocol used in clinical studies. This structural feature is particularly relevant for laboratory stability and handling.
Mechanism of Action: The Dual GIP/GLP-1 Pathway
Most peptides in this class — semaglutide being the prime example — act exclusively on the GLP-1 receptor. Tirzepatide activates both pathways simultaneously:
- GLP-1 receptor: regulates glucose-dependent insulin secretion, slows gastric emptying, and acts on satiety centres.
- GIP receptor: involved in lipid metabolism and amplification of the insulin response — a pathway long underestimated in research before tirzepatide studies.
The working hypothesis is that simultaneous activation of both receptors produces a synergistic effect exceeding the sum of each individually. Comparative data supports this, though the precise mechanism of synergy remains under discussion in the literature.
Research Data: SURPASS and SURMOUNT Trials
Two major clinical trial programmes have shaped tirzepatide research.
The SURPASS programme evaluated the peptide in the context of type 2 diabetes. In the head-to-head trial SURPASS-2, tirzepatide was compared directly with semaglutide 1 mg. All three doses tested (5, 10, and 15 mg) showed greater reductions in HbA1c and body weight than semaglutide — one of the few direct comparisons between two peptides of this class. The full study is available on PubMed (SURPASS-2, PMID 34170647).
The SURMOUNT programme focused on weight reduction. In SURMOUNT-1, participants on the highest dose showed a mean body weight reduction of around 20% over 72 weeks — figures never previously observed with a GLP-1 agonist alone. See PubMed (SURMOUNT-1, PMID 35658024).
Important note: these results come from controlled clinical trials. They describe the behaviour of the molecule in a research context and do not constitute a usage recommendation.
Tirzepatide vs Semaglutide vs Retatrutide
This is probably the most frequently asked question in peptide research circles. All three peptides belong to the same broad class but differ fundamentally in mechanism.
| Peptide | Target receptors | Generation |
|---|---|---|
| Semaglutide | GLP-1 (mono-agonist) | First |
| Tirzepatide (Mounjaro) | GIP + GLP-1 (dual agonist) | Second |
| Retatrutide | GIP + GLP-1 + glucagon (triple agonist) | Third |
The logic follows a stepwise progression: each generation adds one receptor. Semaglutide acts on one pathway, tirzepatide on two, retatrutide on three — adding the glucagon receptor, which is involved in energy expenditure. Retatrutide is still in clinical evaluation at the time of writing, while tirzepatide has a substantially larger body of published evidence.
For further reading, see our semaglutide research guide, our retatrutide research guide, and the dedicated retatrutide vs semaglutide comparison.
Explore Our Metabolic Research Peptides
Looking to compare options available for research? Browse our GLP/GIP peptide range:
- Semaglutide 5mg — GLP-1 Peptide
- Retatrutide 6mg/12mg/20mg — Triple Agonist
- MetaboBurn Stack — Metabolic Peptide Formula
The Pen Format for Research
Our peptides are supplied in a pre-assembled pen format rather than the classic vial. For research purposes, this primarily means improved dosing precision: the setting is adjusted by graduation, without manual reconstitution or syringe withdrawal at each use. It also reduces the risk of handling errors and cross-contamination between samples.
Storage and Handling
Like most peptides in this class, tirzepatide is stable under refrigeration (2–8°C). Protected from light and once the solution is prepared, it maintains integrity for several weeks under these conditions. Repeated freeze-thaw cycles should be avoided, as they degrade the peptide structure.
Legal Status in Europe
Across Europe, tirzepatide may be acquired for scientific research purposes. It is not sold or presented here as a product intended for human use or therapeutic application. Any use outside an in vitro research framework is the sole responsibility of the acquirer. For country-specific guidance, see our article “Buying Peptides in France — What is Legal”.
Scientific References
- Frías JP et al. Tirzepatide versus Semaglutide Once Weekly in Patients with Type 2 Diabetes. N Engl J Med, 2021. PubMed PMID 34170647
- Jastreboff AM et al. Tirzepatide Once Weekly for the Treatment of Obesity. N Engl J Med, 2022. PubMed PMID 35658024
- Coskun T et al. Tirzepatide is an imbalanced and biased dual GIP and GLP-1 receptor agonist. JCI, 2022. PubMed PMID 35167498
Frequently Asked Questions
Are tirzepatide and Mounjaro the same thing?
Yes. Mounjaro is the brand name for tirzepatide (Zepbound being another brand by Eli Lilly). The molecule is identical.
What is the difference between tirzepatide and semaglutide?
Semaglutide acts only on the GLP-1 receptor. Tirzepatide activates both GIP and GLP-1 receptors. In the head-to-head SURPASS-2 trial, tirzepatide demonstrated stronger effects across all doses tested.
Is tirzepatide more potent than retatrutide?
They belong to different generations. Retatrutide adds a third receptor target (glucagon), but remains in clinical evaluation, while tirzepatide has a completed trial dataset available.
Disclaimer: This product is intended exclusively for scientific and experimental research. Not intended for human or animal consumption, nor for diagnostic or therapeutic use. The information above is provided for documentation purposes and is based on published clinical trial data.